Search research articles
Contact Us
Filters
Showing results (121-130 of 136) with videos related to
Page
of 14
Sort By:
Pigment Cell Research
|
January 7, 1999
Melanoma x macrophage fusion hybrids acquire increased melanogenesis and metastatic potential: altered N-glycosylation as an underlying mechanism
S A Sodi, A K Chakraborty, J T Platt, et al.
Plos One
|
July 13, 2022
Comparison of anterior nares CT values in asymptomatic and symptomatic individuals diagnosed with SARS-CoV-2 in a university screening program
Samantha M Hall, Lena Landaverde, Christopher J Gill, et al.
Cancer Discovery
|
December 15, 2012
Genotype-selective combination therapies for melanoma identified by high-throughput drug screening
Matthew A Held, Casey G Langdon, James T Platt, et al.
Oncotarget
|
October 21, 2015
SMAC mimetic Debio 1143 synergizes with taxanes, topoisomerase inhibitors and bromodomain inhibitors to impede growth of lung adenocarcinoma cells
Casey G Langdon, Norbert Wiedemann, Matthew A Held, et al.
Cancer Cell
|
December 17, 2011
β-catenin signaling controls metastasis in Braf-activated Pten-deficient melanomas
William E Damsky, David P Curley, Manjula Santhanakrishnan, et al.
JAMA Network Open
|
February 25, 2022
Association of COVID-19 Quarantine Duration and Postquarantine Transmission Risk in 4 University Cohorts
Andrew Bo Liu, Dan Davidi, Hannah Emily Landsberg, et al.
Oncotarget
|
October 8, 2016
RGS6 is an essential tumor suppressor that prevents bladder carcinogenesis by promoting p53 activation and DNMT1 downregulation
Jianqi Yang, Lance T Platt, Biswanath Maity, et al.
Molecular Cancer Therapeutics
|
March 16, 2017
Combinatorial Screening of Pancreatic Adenocarcinoma Reveals Sensitivity to Drug Combinations Including Bromodomain Inhibitor Plus Neddylation Inhibitor
Casey G Langdon, James T Platt, Robert E Means, et al.
Cancer Cell
|
January 14, 2015
mTORC1 activation blocks BrafV600E-induced growth arrest but is insufficient for melanoma formation
William Damsky, Goran Micevic, Katrina Meeth, et al.
Cancer Research
|
February 26, 2015
PDK1 and SGK3 Contribute to the Growth of BRAF-Mutant Melanomas and Are Potential Therapeutic Targets
Marzia Scortegagna, Eric Lau, Tongwu Zhang, et al.
Page
of 14
Search research articles
Search
Showing results (121-130 of 136) with videos related to
Sort By:
Page
of 14
Pigment Cell Research
|
January 7, 1999
Melanoma x macrophage fusion hybrids acquire increased melanogenesis and metastatic potential: altered N-glycosylation as an underlying mechanism
S A Sodi, A K Chakraborty, J T Platt, et al.
Plos One
|
July 13, 2022
Comparison of anterior nares CT values in asymptomatic and symptomatic individuals diagnosed with SARS-CoV-2 in a university screening program
Samantha M Hall, Lena Landaverde, Christopher J Gill, et al.
Cancer Discovery
|
December 15, 2012
Genotype-selective combination therapies for melanoma identified by high-throughput drug screening
Matthew A Held, Casey G Langdon, James T Platt, et al.
Oncotarget
|
October 21, 2015
SMAC mimetic Debio 1143 synergizes with taxanes, topoisomerase inhibitors and bromodomain inhibitors to impede growth of lung adenocarcinoma cells
Casey G Langdon, Norbert Wiedemann, Matthew A Held, et al.
Cancer Cell
|
December 17, 2011
β-catenin signaling controls metastasis in Braf-activated Pten-deficient melanomas
William E Damsky, David P Curley, Manjula Santhanakrishnan, et al.
JAMA Network Open
|
February 25, 2022
Association of COVID-19 Quarantine Duration and Postquarantine Transmission Risk in 4 University Cohorts
Andrew Bo Liu, Dan Davidi, Hannah Emily Landsberg, et al.
Oncotarget
|
October 8, 2016
RGS6 is an essential tumor suppressor that prevents bladder carcinogenesis by promoting p53 activation and DNMT1 downregulation
Jianqi Yang, Lance T Platt, Biswanath Maity, et al.
Molecular Cancer Therapeutics
|
March 16, 2017
Combinatorial Screening of Pancreatic Adenocarcinoma Reveals Sensitivity to Drug Combinations Including Bromodomain Inhibitor Plus Neddylation Inhibitor
Casey G Langdon, James T Platt, Robert E Means, et al.
Cancer Cell
|
January 14, 2015
mTORC1 activation blocks BrafV600E-induced growth arrest but is insufficient for melanoma formation
William Damsky, Goran Micevic, Katrina Meeth, et al.
Cancer Research
|
February 26, 2015
PDK1 and SGK3 Contribute to the Growth of BRAF-Mutant Melanomas and Are Potential Therapeutic Targets
Marzia Scortegagna, Eric Lau, Tongwu Zhang, et al.
Page
of 14